Syndax Pharmaceuticals
Presence
Syndax Pharmaceuticals is one of the...
Syndax Pharmaceuticals is a company listed under the stock ticker SNDX (US).
Executives
View the org chart displaying its 17 main executives
Most searched biographies at Syndax Pharmaceuticals
- Michael Metzger, Director and Chief Executive Officer
- Jennifer Jarrett, Director
- Pierre Legault, Director
Popular executive movements at Syndax Pharmaceuticals
- Steve Sabus, Chief Commercial Officer, has left the company (posted on March 24 2024).
- Steven Closter has joined the company as Chief Commercial Officer (posted on March 24 2024).
Create your alert
to follow the executive moves at Syndax Pharmaceuticals.
Pharmaceuticals
Syndax Pharmaceuticals has 1,865 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
- Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Syndax Pharmaceuticals
- Syndax Announces Participation at Stifel Healthcare Conference | Syndax Pharmaceuticals, Inc.
- Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis | Syndax Pharmaceuticals, Inc.
- Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023 | Syndax Pharmaceuticals, Inc.
- Syndax Announces Participation at the Citi 18th Annual BioPharma Conference | Syndax Pharmaceuticals, Inc.
- Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update | Syndax Pharmaceuticals, Inc.
- Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease | Syndax Pharmaceuticals, Inc.
- Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023 | Syndax Pharmaceuticals, Inc.
- Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022 | Syndax Pharmaceuticals, Inc.
- Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) | Syndax Pharmaceuticals, Inc.
- Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer | Syndax Pharmaceuticals, Inc.
- View more press releases Close
Social media about Syndax Pharmaceuticals
- Syndax Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Syndax Pharmaceuticals on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Michael Metzger 
Call Syndax Pharmaceuticals at +1 781...
